Stoke Therapeutics rises on update for rare disease drug

Stoke Therapeutics

08/08/2022 18:32

** Shares of Stoke Therapeutics Inc  STOK.O  rise 13.5% to
$19.06 - set to post the biggest one-day jump in over two years
    ** Plans to release data in Q4 from three clinical trials
testing its drug STK-001 in children and adolescents with Dravet
syndrome, a severe genetic form of epilepsy  urn:newsml:reuters.com:*:nBw9vwMyZa
    ** Also plans to report seizure frequency data from certain
dose cohorts in two of these studies
    ** Brokerage Cowen says Q4 update will be the next key
catalyst for the stock as it will provide clearer look at the
drug's clinical profile 
    ** Despite session's gain, stock down 20.6% YTD, compared
with a ~12% decline in the Nasdaq Biotech index  .NBI 

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))